151 related articles for article (PubMed ID: 19170302)
1. A prospective baseline versus on-treatment study assessing patient perceptions of using a smaller needle when injecting intramuscular interferon beta-1 a (Avonex).
Freedman SM; Cox D; Rosebrough T
J Neurosci Nurs; 2008 Dec; 40(6):350-5. PubMed ID: 19170302
[TBL] [Abstract][Full Text] [Related]
2. An open-label, multicenter study to evaluate the safe and effective use of the single-use autoinjector with an Avonex® prefilled syringe in multiple sclerosis subjects.
Phillips JT; Fox E; Grainger W; Tuccillo D; Liu S; Deykin A
BMC Neurol; 2011 Oct; 11():126. PubMed ID: 21999176
[TBL] [Abstract][Full Text] [Related]
3. Single-use autoinjector for once-weekly intramuscular injection of IFNβ-1a.
Limmroth V; Gerbershagen K
Expert Opin Drug Deliv; 2014 Dec; 11(12):1969-78. PubMed ID: 25255732
[TBL] [Abstract][Full Text] [Related]
4. Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction.
Hupperts R; Becker V; Friedrich J; Gobbi C; Salgado AV; Sperling B; You X
Expert Opin Drug Deliv; 2015 Jan; 12(1):15-25. PubMed ID: 25430947
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of intramuscular interferon beta-1a compared with subcutaneous interferon beta-1a in relapsing MS: results from PROOF.
Minagara A; Murray TJ;
Curr Med Res Opin; 2008 Apr; 24(4):1049-55. PubMed ID: 18315940
[TBL] [Abstract][Full Text] [Related]
6. Self-injection anxiety training: a treatment for patients unable to self-inject injectable medications.
Mohr DC; Cox D; Merluzzi N
Mult Scler; 2005 Apr; 11(2):182-5. PubMed ID: 15794392
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of EMLA cream to reduce fear and pain associated with interferon beta-1a injection in patients with multiple sclerosis.
Buhse M
J Neurosci Nurs; 2006 Aug; 38(4):222-6. PubMed ID: 16924997
[TBL] [Abstract][Full Text] [Related]
8. The effects of intramuscular interferon beta-Ia in patients at high risk for development of multiple sclerosis: a post hoc analysis of data from CHAMPS.
O'Connor P;
Clin Ther; 2003 Nov; 25(11):2865-74. PubMed ID: 14693310
[TBL] [Abstract][Full Text] [Related]
9. Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a.
Rudick RA; Pace A; Rani MR; Hyde R; Panzara M; Appachi S; Shrock J; Maurer SL; Calabresi PA; Confavreux C; Galetta SL; Lublin FD; Radue EW; Ransohoff RM
Neurology; 2009 Jun; 72(23):1989-93. PubMed ID: 19506220
[TBL] [Abstract][Full Text] [Related]
10. A novel needle for subcutaneous injection of interferon beta-1a: effect on pain in volunteers and satisfaction in patients with multiple sclerosis.
Jaber A; Bozzato GB; Vedrine L; Prais WA; Berube J; Laurent PE
BMC Neurol; 2008 Oct; 8():38. PubMed ID: 18845005
[TBL] [Abstract][Full Text] [Related]
11. [Pharmacological and clinical profile of IFNbeta-1a (Avonex IM Injection Syringe 30 microg].
Sumino R
Nihon Yakurigaku Zasshi; 2007 Mar; 129(3):209-17. PubMed ID: 17379973
[No Abstract] [Full Text] [Related]
12. Weekly IM interferon beta-1a in multiple sclerosis patients over 50 years of age.
Lampl C; You X; Limmroth V
Eur J Neurol; 2012 Jan; 19(1):142-8. PubMed ID: 21718390
[TBL] [Abstract][Full Text] [Related]
13. Intramuscular interferon beta-1a in chronic inflammatory demyelinating polyradiculoneuropathy.
Hughes RA; Gorson KC; Cros D; Griffin J; Pollard J; Vallat JM; Maurer SL; Riester K; Davar G; Dawson K; Sandrock A;
Neurology; 2010 Feb; 74(8):651-7. PubMed ID: 20177118
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, open-label, phase II study of the immunogenicity and safety of a new prefilled syringe (liquid) formulation of Avonex in patients with multiple sclerosis.
Phillips JT; Rice G; Frohman E; Vande Gaer L; Scott T; Haas J; Eggenberger E; Freedman MS; Stuart W; Cunha L; Jacobs L; Oger J; Arnold D; Murray TJ; DiBiase M; Jethwa V; Goelz S
Clin Ther; 2004 Apr; 26(4):511-21. PubMed ID: 15189748
[TBL] [Abstract][Full Text] [Related]
15. Injection anxiety remains a long-term barrier to medication adherence in multiple sclerosis.
Turner AP; Williams RM; Sloan AP; Haselkorn JK
Rehabil Psychol; 2009 Feb; 54(1):116-21. PubMed ID: 19618711
[TBL] [Abstract][Full Text] [Related]
16. Treatment of early-onset multiple sclerosis with intramuscular interferonbeta-1a: long-term results.
Ghezzi A; Amato MP; Capobianco M; Gallo P; Marrosu MG; Martinelli V; Milanese C; Moiola L; Milani N; La Mantia L; Patti F; Pozzilli C; Trojano M; Comi G; Zaffaroni M;
Neurol Sci; 2007 Jun; 28(3):127-32. PubMed ID: 17603763
[TBL] [Abstract][Full Text] [Related]
17. Will new injection devices for interferon β-1a s.c. affect treatment adherence in patients with multiple sclerosis? An expert opinion in the Middle East.
Deleu D; Alsharoqi I; Al Jumah MA; Al Tahan AR; Bohlega S; Dahdaleh M; Inshasi J; Khalifa A; Szólics M; Yamout BI
Int J Neurosci; 2011 Apr; 121(4):171-5. PubMed ID: 21329472
[TBL] [Abstract][Full Text] [Related]
18. Adherence to therapy: using an evidence-based protocol.
Moore LA; Kaufman MD; Algozzine R; Irish N; Martin M; Posey CR
Rehabil Nurs; 2007; 32(6):227-32. PubMed ID: 18065143
[TBL] [Abstract][Full Text] [Related]
19. What is new in the treatment of multiple sclerosis?
Weinstock-Guttman B; Jacobs LD
Drugs; 2000 Mar; 59(3):401-10. PubMed ID: 10776827
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of intramuscular interferon beta-1a in patients with clinically isolated syndrome: analysis of subgroups based on new risk criteria.
O'Connor P; Kinkel RP; Kremenchutzky M
Mult Scler; 2009 Jun; 15(6):728-34. PubMed ID: 19482863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
